Milbank Advised German Equity Partners IV On The Sale Of Uroviva To Affidea
Milbank Advised German Equity Partners IV On The Sale Of Uroviva To Affidea
The law firm’s team guided on corporate and tax aspects of the transaction
International law firm Milbank LLP has counseled German Equity Partners IV (managed by independent investment company ECM Equity Capital Management GmbH) on the sale of its majority stake in Uroviva Group to Affidea B.V.
Uroviva Group is one of the leading private providers of medical services in urology, gynecology and oncology in Switzerland.
It has 250 employees and operates from 16 locations in Zurich, Lucerne, Zug, Solothurn, and Aargau. Its services include outpatient care and inpatient treatments.
Affidea B.V. is a leading pan-European provider of specialized healthcare services and a portfolio company of the publicly listed Groupe Bruxelles Lambert S.A.
Since 1995, ECM has been a growth partner for mid-sized enterprises and entrepreneurs in German-speaking Europe. It raised five private equity funds GEP I-V with aggregate equity commitments of over €1 billion. It currently invests out of its fifth fund, GEP V (€325 million).
The funds are invested in leading mid-market companies for succession solutions, partnership transactions and corporate spin-offs.
The Milbank team was led by partner Michael Bernhardt. It included associates Sarah-Maria Resch, Andreas Rief and Josephine Schuster (corporate/M&A, Frankfurt) and partner Matthias Schell and associate Nikolas Wolf (tax, Munich).
If you have a news or deal publication or would like to collaborate on content, columns, or article publications, connect with the Legal Era News Network Team and email us at info@legalera.in or call us on +91 8879634922.
